GSK to take 10% stake in Germany's CureVac for $163 mln

Britain's GSK said on Monday it would invest 130 million pounds ($163 million) to buy a 10% stake in Germany's CureVac, launching a collaboration to develop up to five mRNA-based vaccines with technology already being used by the biotech company to develop a COVID-19 vaccine. CureVac's existing COVID-19 mRNA and rabies vaccines research programmes are not included in the deal, the companies said.

Britain's GSK said on Monday it would invest 130 million pounds ($163 million) to buy a 10% stake in Germany's CureVac, launching a collaboration to develop up to five mRNA-based vaccines with technology already being used by the biotech company to develop a COVID-19 vaccine.

CureVac's existing COVID-19 mRNA and rabies vaccines research programmes are not included in the deal, the companies said. CureVac said in June it would start human trials of an experimental vaccine for treating COVID-19 in the country.

The company, based in Tuebingen and backed by the Bill & Melinda Gates Foundation, is using the so-called messenger RNA approach that has also been adopted by BioNTech and its partner Pfizer as well as Moderna. ($1 = 0.7977 pounds)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)